Psoriasis Treatment Market Size, Share & Industry Analysis, By Drug Class (TNF Inhibitors, Interleukin Inhibitors [IL-17, IL-23/p19, and IL-12/23 p40 Inhibitors], PDE4 Inhibitors, JAK Inhibitors, and Corticosteroids), By Indication (Plaque Psoriasis, Psoriatic Arthritis, Guttate Psoriasis, and Inverse Psoriasis), By Product Type (Biologics and Non-Biologics), By Route of Administration (Oral, Parenteral/Systemic, and Topical), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and Regional Forecast, 2026-2034

The global psoriasis treatment market size was valued at USD 29.26 billion in 2025. The market is projected to grow from USD 31.51 billion in 2026 to USD 59.89 billion by 2034, exhibiting a CAGR of 8.36% during the forecast period. North America dominated the psoriasis treatment market with a market share of 74.74% in 2025.

Psoriasis is an autoimmune inflammatory disorder characterized by overproduction of skin cells, leading to an itchy, painful skin condition with red lesions and plaque formation. The global market is growing as patients and healthcare providers shift from short-term symptom control to long-term disease management with targeted and convenient therapies. The growth is mainly driven by increasing awareness of psoriasis as a systemic inflammatory disease and by the growing demand for better skin clearance, fewer flares, and improved quality of life. Additionally, the increasing use of IL-17, IL-23, TYK2, and advanced topical mechanisms is helping physicians treat patients who do not respond adequately to conventional therapies. These factors collectively are resulting in psoriasis treatment solutions becoming an important part of chronic dermatology care. The market is witnessing strategic collaborations among key players to commercialize its growth potential.

• For instance, in November 2025, Medidata expanded its collaboration with CTI Clinical Trial and Consulting to use Medidata Patient Experience for patient-centric studies across oncology, metabolic, cardiovascular, CNS, and immune conditions. The partnership aimed to support more flexible and patient-friendly clinical trials by improving digital engagement and decentralized trial workflows.

Furthermore, major players, such as AbbVie Inc., Novartis AG, Johnson & Johnson Services, Inc., and Pfizer Inc., are actively participating in strategic collaborations and acquisitions to expand their offerings, focusing on research and development alongside pipeline expansion to enhance market access and strengthen their market presence.

Download Free sample to learn more about this report.

PSORIASIS TREATMENT MARKET TRENDS

Increasing Utilization of IL-17 and IL-23 Inhibitors for Treatment of Moderate-to-Severe Psoriasis is a Prominent Trend Observed in Market

A key global market trend observed is the growing adoption of IL-17 and IL-23 pathway inhibitors. The drug class has gained significant importance in the treatment pathway due to durable disease control. Patients with more severe disease require stronger immune-pathway control to reduce relapses and improve quality of life. These inhibitors target a key inflammatory pathway involved in plaque formation, thus becoming highly preferred for sustained control with convenient dosing schedules, driven by innovative therapies launches and regulatory approvals from key companies.

As dermatologists increasingly target PASI 90, PASI 100, complete clearance, and long-term remission, companies are strengthening clinical evidence and expanding product labels for these biologics. Regulatory approval for new product launches in this segment further strengthens its growth potential.

• For instance, in May 2025, Arcutis Biotherapeutics, Inc. received approval from the U.S. FDA for the supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. Therefore, the trend is expected to shape future treatment standards for moderate-to-severe psoriasis and to support the adoption of premium therapies. 

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Prevalence of Chronic Psoriasis to Propel Market Growth

Psoriasis is a chronic immune-mediated disease that causes recurring skin inflammation, itching, pain, scaling, and visible plaques, often affecting quality of life and requiring ongoing care. The market is expected to grow as the global patient burden continues to drive steady demand for long-term, effective treatment options. The growing patient pool is particularly important for moderate-to-severe psoriasis, where patients may not respond adequately to conventional topical therapy or phototherapy and may require advanced systemic treatment. As awareness improves, more patients are entering dermatology and rheumatology care pathways, which is increasing the use of targeted therapies. Also, biosimilars are improving affordability and helping expand access to biologic therapy in cost-sensitive settings. These factors are driving global psoriasis treatment market growth.

• For instance, the National Psoriasis Foundation reported in December 2022 that 125 million people globally, i.e., 2-3% of the global population, have psoriasis. This large and unevenly distributed patient base supports continued demand for improved topical, oral, biologic, and biosimilar therapies.

MARKET RESTRAINTS

High Cost of Biologic and Advanced Systemic Therapies Limiting Wider Adoption of Psoriasis Treatment

The market faces limited adoption due to the high cost of biologics and systemic therapies. Such low adoption is restraining the market as these therapies remain expensive for many patients, payers, and healthcare systems. Moderate-to-severe psoriasis often requires long-term treatment, so high monthly or per-dose prices can quickly become a recurring affordability burden. Even when these therapies offer stronger skin clearance and better disease control than older options, access may depend on insurance approval, formulary placement, prior authorization, patient assistance programs, and out-of-pocket costs.

• For instance, in December 2025, Clinics in Dermatology published an article titled ‘Equitable access to biologic therapies in a psoriasis safety-net clinic: A retrospective cohort study’ that reported that access to biologic therapies for psoriasis remains uneven among uninsured or underinsured patients, despite safety-net systems, and manufacturer assistance.

MARKET OPPORTUNITIES

Rising Opportunity in Emerging Markets with Undiagnosed Patient Pools and Increasing Awareness to Offer Lucrative Opportunities

The significant opportunity for the global market growth is the increasing awareness in emerging markets. A large share of patients remains undiagnosed, undertreated, or managed only with basic topical therapies in these developing countries. In many developing countries, limited dermatology access, low awareness of psoriasis as a chronic immune-mediated disease, social stigma, and affordability barriers delay diagnosis and specialist referral. As healthcare systems improve and dermatology awareness increases, more patients with moderate-to-severe psoriasis are likely to enter formal treatment pathways, creating a larger addressable pool for prescription therapies. Key companies are participating in strategic collaborations to organize campaigns to increase awareness and drive market growth.

• For instance, in August 2025, Boehringer Ingelheim International GmbH, in partnership with the National Psoriasis Foundation, launched a new campaign to increase awareness and education for generalized pustular psoriasis (GPP).

MARKET CHALLENGES

Uneven Access to Advanced Therapies Across Regions to Challenge Market Growth

The market may face growth challenges as access to advanced therapies remains uneven across countries and healthcare systems. The adoption of these therapies depends heavily on reimbursement coverage, specialist availability, formulary inclusion, and patient affordability, among other factors. In developed markets, patients have better access to dermatologists, specialty pharmacies, biologic monitoring, and payer-supported treatment pathways. However, in many emerging and price-sensitive markets, patients may remain dependent on topical therapies, conventional systemic drugs, or delayed treatment due to high biologic costs and limited reimbursement. This creates a gap between clinical innovation and the availability of real-world treatments. As a result, even when newer therapies show strong skin clearance and long-term disease control, their uptake may remain limited if healthcare systems cannot support broad access.

• For instance, in September 2025, the WHO noted that biologic therapies offer important benefits. Still, their high costs have limited access for many patients globally, especially in low- and middle-income countries, where constrained healthcare budgets make biosimilars important for improving affordability.

Segmentation Analysis

By Drug Class

Interleukins Inhibitors Segment Lead Due to Strong Targeted Efficacy in Moderate-to-Severe Psoriasis

Based on drug class, the market is categorized TNF Inhibitors, interleukins inhibitors, PDE4 inhibitors, TYK2 inhibitors, JAK inhibitors, corticosteroids, vitamin D analogs, retinoids, and others.

The interleukins inhibitors segment dominated the global psoriasis treatment market share. The high share is allocated due to healthcare providers' increasing preference for targeted biologics that act on the IL-17, IL-23, and IL-12/23 pathways. These therapies are widely used in moderate to severe plaque psoriasis as they provide stronger skin clearance and better long-term disease control than many conventional systemic treatments. Additionally, the entry of ustekinumab biosimilars is improving affordability and expanding access to interleukin-based biologic therapy.

• For instance, in March 2025, Hansoh Pharma announced late-breaking Phase 2 results for HS-20137, an IL-23-targeting monoclonal antibody developed with Qyuns Therapeutics, for plaque psoriasis.

The TYK2 inhibitors segment is expected to grow at a CAGR of 34.96% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Indication

Plaque Psoriasis Segment Dominates Owing to Large Patient Pool and High Treatment Demand

Based on indication, the market is segmented into plaque psoriasis, psoriatic arthritis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and others.

In 2025, the plaque psoriasis segment held the dominant share as it is the most commonly treated form of psoriasis. The segment also accounts for the largest eligible patient pool for topical, oral, biologic, and biosimilar therapies. Also, higher diagnosis rates, strong product innovation, and the increasing use of systemic therapies in patients with moderate-to-severe disease support the segment’s growth. Moreover, new topical approvals are strengthening treatment options for patients across mild-to-severe plaque psoriasis.

• For instance, in April 2025, Health Canada approved NDUVRA (tapinarof cream, 1%) for the topical treatment of plaque psoriasis in adults, adding a novel non-steroidal option to the segment.

The psoriatic arthritis segment is projected to grow at a 11.51% CAGR during the forecast period for the global market.

By Product Type

Biologics Segment Lead Due to Higher Skin Clearance and Long-term Disease Control

Based on product type, the market is segmented into biologics and non-biologics.

The biologics segment held the largest share in the market. The segment's dominant position was driven by the strong role of biologics in treating moderate-to-severe psoriasis, especially among patients who do not respond adequately to topical therapy, phototherapy, or conventional systemic drugs. Biologics are preferred as they target specific immune pathways and support durable responses in the management of chronic diseases. Biosimilar approvals and launches are further strengthening this segment by reducing cost barriers and increasing treatment access.

• For instance, in November 2025, Hikma Pharmaceuticals launched STARJEMZA (ustekinumab-hmny) in the U.S., a biosimilar referencing Stelara, strengthening biologic competition in plaque psoriasis and psoriatic arthritis.

The non-biologics segment is projected to grow at a 13.79% CAGR during the forecast period.

By Route of Administration

Parenteral Therapies Dominate Due to Strong Adoption of Injectable Biologics

Based on route of administration, the market is segmented into oral, parenteral/systemic, and topical.

The parenteral/systemic segment held the dominant share due to the high use of injectable biologics and biosimilars in moderate-to-severe plaque psoriasis and psoriatic arthritis. These therapies are typically used for patients requiring systemic immune control, which increases their value contribution compared with topical and oral options. The segment is also supported by prefilled syringes, auto injectors, and reimbursed biologic pathways that improve long-term treatment continuation.

• For instance, in May 2026, Samsung Bioepis launched Ustekinumab BS 45 mg Syringe for S.C. Injection “NIPRO” in Japan, supporting broader access to subcutaneous biologic therapy. Such developments further drive the segment's growth.

The oral segment is projected to grow at a CAGR of 14.24% during the forecast period.

By Age Group

Larger Patient Pool in Adult Segment to Lead Growth

Based on age group, the market is bifurcated into pediatrics and adults.

The adults segment dominated the global market on the basis of age group. Psoriasis is more frequently diagnosed in adult populations. Adult patients are more to receive long-term systemic treatment. This larger eligible treatment pool, combined with wider reimbursement coverage and stronger physician familiarity with adult systemic therapy, is expected to support the continued dominance of the adults’ segment.

• For instance, in December 2025, Takeda announced positive Phase 3 results for zasocitinib, a once-daily oral TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis. The studies met all primary and ranked secondary endpoints, supporting continued innovation focused on adult psoriasis patients requiring systemic therapy.

The pediatrics segment is projected to grow at a CAGR of 11.14% over the forecast period.

By Distribution Channel

Specialty Pharmacies Segment Led Due to Specialist-led Biologic Prescribing and Monitoring

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.

In 2025, specialty pharmacies dominated the market due to the large share of biologics, biosimilars, and advanced systemic therapies that require specialist prescription, reimbursement approval, baseline screening, and long-term safety monitoring. Patients with moderate-to-severe psoriasis are commonly treated through dermatology or rheumatology care pathways, underscoring the importance of specialist channels for access to high-value therapies.

• For instance, in April 2025, LEO Pharma partnered with the Parker Institute at Copenhagen University Hospital to advance research and innovation in medical dermatology—the collaboration aimed to discover molecules that could potentially be integrated into broader pharmaceutical research and development efforts.

The online pharmacies segment is projected to grow at a 16.08% CAGR over the forecast period.

Psoriasis Treatment Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024 at USD 20.32 billion and maintained its leading position in 2025 at USD 21.87 billion. The regional market is growing due to high diagnosis rates, strong dermatology access, and rapid adoption of biologics, biosimilars, and oral systemic therapies.

U.S. Psoriasis Treatment Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 0.49 billion in 2026, accounting for roughly 69.08% of the global market.

Europe

Europe is projected to grow at a CAGR of 7.82% over the coming years, the second-highest among all regions, and reach a valuation of USD 4.35 billion by 2026. The European market has established reimbursement systems and strong clinical guidelines driving growth. Rising adoption of IL-17, IL-23, and advanced oral therapies is improving long-term disease control for moderate-to-severe patients.

U.K Psoriasis Treatment Market

The U.K. market is estimated at USD 0.64 billion in 2026, accounting for roughly 2.02% of the global market.

Germany Psoriasis Treatment Market

Germany's market is projected to reach approximately USD 1.05 billion in 2026, equivalent to around 3.34% of the global market.

Asia Pacific

Asia Pacific market is estimated to reach USD 2.21 billion in 2026 and secure the position of the third-largest region in the market. The market is growing due to a large patient pool, improved diagnostics, and greater access to dermatology care in China, India, Japan, South Korea, and Australia. Local biologic development, biosimilar launches, and expanding healthcare spending are supporting faster adoption of advanced therapies.

Japan Psoriasis Treatment Market

The Japanese market is estimated at around USD 0.61 billion in 2026, accounting for approximately 1.92% of the global market.

China Psoriasis Treatment Market

China's market is projected to be among the largest globally, with 2026 revenues estimated at around USD 0.74 billion, accounting for approximately 2.34% of global sales.

India Psoriasis Treatment Market

The Indian market is estimated at around USD 0.24 billion in 2026, accounting for roughly 0.76% of global revenue.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness considerable growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.81 billion. The market is growing across these regions due to rising awareness of psoriasis, improved specialist care, and the gradual expansion of access to biologic and systemic therapies.

GCC Psoriasis Treatment Market

The GCC market is set to reach USD 0.30 billion in 2026.

South Africa Psoriasis Treatment Market

The South African market is projected to reach approximately USD 0.07 billion by 2026, accounting for roughly 0.23% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Focus on Innovation-led Competition and Biosimilar Expansion to Shape Market Growth

The global psoriasis treatment market is moderately consolidated, with competition led by companies offering established biologics, biosimilars, oral systemic therapies, and advanced topical treatments. Major players such as AbbVie, Novartis, Johnson & Johnson, Eli Lilly, UCB, Amgen, Sun Pharma, Almirall, LEO Pharma, Arcutis, and Bristol Myers Squibb are strengthening their market position through product launches, label expansions, long-term clinical data, and geographic expansion. The market is mainly driven by the shift toward IL-17 and IL-23 inhibitors, rising demand for deeper skin clearance, growing use of biosimilars to improve affordability, and increasing patient preference for oral and non-steroidal topical options.

• For instance, in March 2026, Johnson & Johnson announced U.S. FDA approval of ICOTYDE (icotrokinra), a once-daily IL-23 receptor-targeted oral peptide for moderate-to-severe plaque psoriasis. The product offers an innovative systemic option for patients cycling through topical therapies who need stronger disease control.

Other notable participants in the market include Teva, Alvotech, Sandoz, Celltrion, Biocon Biologics, Formycon, Fresenius Kabi, Organon, Takeda, and Boehringer Ingelheim. These companies are expected to focus on biosimilar launches, targeted oral therapies, non-steroidal topical products, rare psoriasis indications, and emerging-market expansion. Specialized companies are competing through differentiated mechanisms, better dosing convenience, and therapies for difficult-to-treat psoriasis populations.

LIST OF KEY PSORIASIS TREATMENT COMPANIES PROFILED IN REPORT

• AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Amgen Inc. (U.S.)
• UCB S.A. (Belgium)
• Sun Pharmaceutical Industries Ltd.(India)
• Almirall, S.A (Spain)
• Arcutis Biotherapeutics, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• March 2026: Bristol Myers Squibb received U.S. FDA approval for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is approved for PsA.
• March 2026: Johnson & Johnson received approval from the U.S. FDA for ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older.
• February 2026: Pfizer Inc. collaborated with Arrotex Pharmaceuticals for Enbrel (etanercept) in Australia. Under the agreement, Arrotex will be responsible for representing Pfizer’s Enbrel across Australian pharmacies, hospitals, and prescriber channels. Enbrel is approved for the treatment of arthritis and psoriasis.
• November 2025: Hikma Pharmaceuticals launched STARJEMZA (ustekinumab-hmny) in the U.S., a biosimilar referencing Stelara, strengthening biologic competition in plaque psoriasis and psoriatic arthritis.
• October 2025: Fangzhou Inc. collaborated with Shanghai Fosun Pharmaceutical (Group) Co., Ltd to build an extensive partnership in AI-powered chronic disease management, focused on psoriasis and other autoimmune conditions.
• October 2025: Organon Canada launched NDUVRA (tapinarof cream, 1%) for the topical treatment of plaque psoriasis in adults. The development marks an important milestone for patients in Canada, offering a new treatment option for those suffering from this chronic condition.

REPORT COVERAGE

The report provides a detailed global psoriasis treatment market analysis across the pharmaceutical and dermatology care value chain. The report covers key market segments and also evaluates major factors supporting market growth. Additionally, the report examines market restraints and challenges. The report further analyzes competitive positioning, recent product launches, regulatory approvals, partnerships, collaborations, acquisitions, and pipeline advancements by key players in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation